Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. It will seriously reduce the quality of life of patients and bring a huge burden to their families and society, so treating PD is urgent. The most important pathological changes of PD is the massive cell death of the neuromelanin-containing dopaminergic neurons of the substantia nigra, resulting in significant reduction in the content of the striatum dopamine (DA). Additionally, there is evidence that oxidative stress causes neuronal death and neural dysfunction, suggesting an important pathogenic role for oxidative stress in PD. In response to this, researchers have tried a variety of treatments, but still failed to achieve effective treatment for PD. The development of nanozymes provides new strategies for treating PD. They have high reactive oxygen species (ROS) scavenging capacity, and can reduce oxidative stress caused by ROS, thus further protect nerve cells. It is believed that nanozymes will be a research hotspot in the field of PD treatment for a long time.
So far, many nanozymes have been found to have powerful antioxidant properties and are used for treating PD. For example, Mn3O4 nanozymes with flower-like morphology possessed multiantioxidant-enzyme-like catalytic activities including superoxide dismutase, catalase, and glutathione peroxidase. They can robustly rescue the cells from oxidative damage and thereby having the potential to treat PD[1]. And copper oxide nanozymes also have a variety of oxidase mimicking activities, which could efficiently remove harmful ROS and protect nerve cells against oxidative stress induced by 1-methyl-4-phenylpyridinium (MPP+). They have excellent therapeutic effect on oxidative stress-induced PD[2].
Besides, some metal alloy nanozymes have also been developed for treating PD. For example, PtCu alloy nanozyme has multiple simulated enzyme activities and the ability to scavenge free radicals, which can reduce the level of oxidative stress, thereby achieving the treatment of PD. Notably, by scavenging ROS, this nanozyme can significantly inhibit cell death and neurotoxicity induced by preformed fibrils (PFF), and can also block the diffusion of pathological α-synuclein from the striatum to the substantia nigra, providing a new strategy for the application of nanozymes in treating PD[3].
Alfa Chemistry can offer a series of nanozymes such as manganese-based nanozymes, copper-based nanozymes and metal alloy nanozymes, which have broad application prospects in treating PD. We will offer the most suitable nanozymes according to customer's detailed requirements. At the same time, we also offer product customization. If you have any questions or needs, please don't hesitate to contact us. Alfa Chemistry will provide you with the most professional service.
References
Please kindly note that our products and services are for research use only.
Alfa Chemistry offers a wide range of nanozymes to help customers succeed in their scientific research. Your inquiries are welcome.
Privacy Policy | Cookie Policy | Copyright © 2026 Alfa Chemistry. All rights reserved.